Lindahl acted as legal counsel when Nanologica recently carried out a rights issue, which was resolved by the board of directors on August 23, 2022, and approved by the extraordinary general meeting on September 15, 2022. The subscription period ended in October 2022 and the outcome shows that the rights issue was subscribed for up to 85 percent, of which Flerie Invest AB subscribed for 36.6 percent in accordance with an underwriting commitment. Nanologica will thus receive approximately MSEK 79.8 before issue costs.
The purpose of the rights issue is to finance intensified efforts and investments in the preparative chromatography business area in order to strengthen the company’s competitiveness and take advantage of the favorable market conditions.
Nanologica’s share is listed on Nasdaq Stockholm Main Market and the company manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility of innovative treatments and medicines in healthcare, for the benefit of patients around the world.
Lindahl’s team consisted of Mårten Steen, Erika Svensson, Helena Lindbäck and Michaela Larsson.
